Creativ-Ceutical is now part of our team. Learn more here.
Log in or register to see all Alerts
Log in Register
Market Access Alerts >December 2021>France
New HTA Decisions in France
December 2021
Drug name
MAVIRET® (glecaprevir / pibrentasvir)
Company
AbbVie
Decision date
18/11/2021
About PHMR
Therapeutic area
Infections
Therapeutic sub area
Hepatitis
Official notice date
07/12/2021
Reimbursement %
Decision (SMR)
Unspecified
Decision (ASMR)
Unspecified
Indication
MAVIRET® is indicated for the treatment of chronic infection with hepatitis C virus (HCV) in adults and children aged 3 years and over.
Decision Type
New examination following the submission of new data
Summary
The committee considered that the newly presented data were not such as to modify the conclusions formulated in the previous opinion of 06 December 2017, in which MAVIRET® was considered to have an ‘important’ actual benefit and provide a minor improvement in actual benefit (ASMR IV) in the treatment of chronic infection with hepatitis C virus (HCV) genotypes 1 to 6 in adults.


PHMR
Berkeley Works
Berkley Grove
London
NW1 8XY

+44 (0)20 3432 7450

info@phmr.com


 Understanding Payers

 Generating Evidence

 Developing Strategies

 Communicating Value

 Market Access Alerts

 Careers

 About us

 Contact us

 Cookie policy

 Privacy